The Trump administration has reversed a rule that allowed undocumented immigrants who were brought to the U.S. as kids to buy ...

FDA clinical trial reveals CBD may cause liver enzyme elevation in 5% of users, with women showing higher vulnerability than men.

The Fund returned approximately +14% during the second quarter, bringing our YTD returns to under +1%. Read more here.

In recent months, the Trump administration has terminated thousands of federally funded medical research grants, gutting $9.5 billion in critical health science efforts. More than half of those cuts — ...

From tariffs to drug pricing to the FDA, biopharma CEOs find themselves pulled into policy discussions on this year’s second quarter earnings calls.

I think that's the case with Vertex. Here are seven reasons why Vertex is a no-brainer stock to buy on the dip.

George Tidmarsh takes over temporarily at CBER following Vinay Prasad’s abrupt departure; Replimmune trial leaders protest ...

President Trump threatened 250% tariffs on pharma; Pfizer CEO contacted Trump about most favored nation pricing; Ex-X CEO joins eMed.

Trump appeared to acknowledge in the interview that his ruthless mass deportation campaign is hurting farms, which rely on ...

Sales of Novo Nordisk's blockbuster Wegovy obesity drug rose 67% in the second quarter despite continued competition from compounded drug makers. The pharma giant last week cut its full-year guidance ...

While pro-lifers continue to cheer the closure of major abortion hubs around the country, Planned Parenthood’s brick-and-mortar hardships only tell part of the story.